Literature DB >> 12409874

Neurogenic bladder dysfunction in patients with myelomeningocele.

Helmut Madersbacher1.   

Abstract

PURPOSE OF REVIEW: The general management strategies in children with myelodysplasia are widely accepted, however diagnostic and therapeutic details still need to be discussed and clarified. RECENT
FINDINGS: Ten articles are reviewed. Two articles are dealing with general clinical aspects; one underlines the need for urodynamics as a prerequisite for an adequate treatment strategy, the other recommends to evaluate adolescents and adults with myelodysplasia, because only the ultimate outcome allows a judgement of how effective our efforts are to achieve the goals. Increased excretion of glycosaminoglycan in myelodysplasia children above 5 years of age could become a marker for beginning bladder damage and deserves further interest. The question whether children with normal urodynamics after closing the spinal cord should be followed or not is clearly answered in a further article which also discusses the results of detethering in these patients. Four articles report on pharmacotherapy with new substances or new ways of application (intravesical oxybutynin, extended release oxybutynin formulation, intravesical resiniferatoxin). The results of collagen injections in children with neurogenic sphincter underactivity clearly demonstrate that the long-term results are disappointing. Last, but not least, a retrospective review on acute abdominal symptoms and signs in children with myelodysplasia clearly shows that these patients should be transferred to a centre because of complex reasons and treatment modalities.
SUMMARY: Urodynamics - abnormal or normal - are a prerequisite for adequate treatment and follow-up in children with myelodysplasia. More studies should focus on adolescents and adults with myelodysplasia to judge the effectiveness of our diagnostic and therapeutic efforts. New ways of application and new developments in pharmacotherapy to relax the overactive detrusor may possibly further decrease the need for surgery in the future. With regards to sphincter underactivity, results with collagen injections in this group of patients are disappointing and provide no alternative to operative treatment options.

Entities:  

Mesh:

Year:  2002        PMID: 12409874     DOI: 10.1097/00042307-200211000-00004

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

Review 1.  Continent bladder stoma.

Authors:  Nigel Timothy Dunglison; Robert Alexander Gardiner
Journal:  World J Urol       Date:  2003-03-21       Impact factor: 4.226

2.  Onabotulinumtoxin A for treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele.

Authors:  Antonio Marte
Journal:  Toxins (Basel)       Date:  2012-12-28       Impact factor: 4.546

3.  The association of age of toilet training and dysfunctional voiding.

Authors:  Steve J Hodges; Kyle A Richards; Ilya Gorbachinsky; L Spencer Krane
Journal:  Res Rep Urol       Date:  2014-10-03

4.  Urodynamic Study Findings Prior to Myelomeningocele Repair in Neonates.

Authors:  Ibrahim Alatas; Kerem Ozel; Nursu Kara; Huseyin Canaz
Journal:  J Pediatr Neurosci       Date:  2020-11-06

Review 5.  The neurogenic bladder: medical treatment.

Authors:  Carla Verpoorten; Gunnar M Buyse
Journal:  Pediatr Nephrol       Date:  2007-12-19       Impact factor: 3.714

Review 6.  Preventing kidney injury in children with neurogenic bladder dysfunction.

Authors:  Faezeh Javadi Larijani; Mastaneh Moghtaderi; Nilofar Hajizadeh; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2013-12

7.  Daily Enema Regimen Is Superior to Traditional Therapies for Nonneurogenic Pediatric Overactive Bladder.

Authors:  Steve J Hodges; Marc Colaco
Journal:  Glob Pediatr Health       Date:  2016-03-04

8.  Profiling placental and fetal DNA methylation in human neural tube defects.

Authors:  E Magda Price; Maria S Peñaherrera; Elodie Portales-Casamar; Paul Pavlidis; Margot I Van Allen; Deborah E McFadden; Wendy P Robinson
Journal:  Epigenetics Chromatin       Date:  2016-02-16       Impact factor: 4.954

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.